| Literature DB >> 22917768 |
Abstract
Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22917768 DOI： 10.1016/j.leukres.2012.08.011
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156